SCHEMBL14877249

SCHEMBL14877249

O=C(c1ccc(Cc2ccc(C(F)(F)F)cc2)cc1)N1CCC(C2CN(C(=O)c3cscn3)C2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 5/20 0.46
GAA P10253 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
HSD11B1 P28845 1/20 0.43
MEN1 O00255 1/20 0.42
HPGD P15428 1/20 0.42
TSHR P16473 1/20 0.42
KMT2A Q03164 1/20 0.42
PRKAB2 O43741 3/20 0.41
PRKAG1 P54619 3/20 0.41
PRKAA2 P54646 3/20 0.41
PRKAA1 Q13131 3/20 0.41
PRKAG3 Q9UGI9 3/20 0.41
PRKAG2 Q9UGJ0 3/20 0.41
PRKAB1 Q9Y478 3/20 0.41
TEAD1 P28347 3/20 0.41
SIGMAR1 Q99720 1/20 0.41
ADRB2 P07550 1/20 0.40
SLC6A7 Q99884 1/20 0.39
FNTA P49354 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14877410 0.91 GPR52 (0.49) MGLLHSD11B1SLC6A7
SCHEMBL15949209 0.87 MGLL (0.60) MGLLGAATDP1MEN1HPGD
SCHEMBL912450 0.87 MGLL (0.60) MGLLGAATDP1MEN1HPGD
SCHEMBL2131216 0.86 TEAD1 (0.43) MGLLGAATDP1HSD11B1MEN1
SCHEMBL14877295 0.83 SLC6A7 (0.54) MGLLHSD11B1SLC6A7
SCHEMBL14877065 0.83 SLC6A7 (0.54) MGLLHSD11B1SLC6A7
SCHEMBL14877213 0.81 RBP4 (0.49) MGLLGAATDP1HSD11B1MEN1
SCHEMBL14877290 0.81 MGLL (0.62) MGLLHPGD
SCHEMBL14877278 0.81 MGLL (0.62) MGLLHPGD
SCHEMBL14877198 0.80 MGLL (0.41) MGLLSLC6A7FNTAFNTB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130244998-A1 PIPERIDIN-4-YL-AZETIDINE DIAMIDES AS MONOACYLGLCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA, NV (BE) 2013-09-19 US disclosed
US-8513423-B2 Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors JANSSEN PHARMACEUTICA, NV (BE) 2013-08-20 US disclosed
US-20130102584-A1 PIPERIDIN-4-YL-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA, NV (BE) 2013-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130102584-A1 PIPERIDIN-4-YL-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS PNLIP, LPL, MGLL MGLL 3/4885GAA 27/4885TDP1 1561/4885
US-20130244998-A1 PIPERIDIN-4-YL-AZETIDINE DIAMIDES AS MONOACYLGLCEROL LIPASE INHIBITORS MGLL, PNLIP, LPL MGLL 1/4885GAA 12/4885TDP1 1602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.